2017 Symptom burden after dialysis initiation and associations with hospitalizations Devin Peipert 1 , Devika Nair 2 , Xuan Cai 3 , Ron Hays 4 , Olalekan Aiyegbusi 5 , Rebecca Frazier 6 , Tamara Isakova 7 1 University of Birmingham, Birmingham, Illinois, UK, 2 Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA, 3 Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA, 4 Division of General Internal Medicine and Health Services Research, Department of Medicine, University of California, Los Angeles, USA, 5 Centre for Patient-Reported Outcomes Research (CPROR), Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK, 6 Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA, 7 Division of Nephrology and Hypertension, Feinberg School of Medicine, Northwestern University, Chicago, USA Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :2017 Aims Symptom burden is distressing for patients living with kidney failure, but there is limited information about the combination of symptoms that best predict healthcare utilization in hemodialysis
At the 12 mg dose: 28.3% average weight loss (about 70 lbs) 45.3% of patients lost 30% or more of their body weight 65.3% of patients dropped below a BMI of 30 Patients with baseline BMI 35 who stayed for 104 weeks lost 30.3% on average (85 lbs), with no plateau in sight Discontinuation due to side effects: 11.3% at 12 mg vs
Pelvic floor dysfunction, specifically dyssynergic defecation, occurs when the muscles that should relax during a bowel movement instead tighten
GLP-1RAs are essential for preventing fractures in people with T2DM because they greatly increase bone mass, trabecular and cortical architecture, and total bone strength
